Securing US Food and Drug Administration approval for its CHS-201 biosimilar Lucentis (ranibizumab) candidate will make a $50m loan payment available to Coherus BioSciences, Inc., under a broader $300m credit facility agreed with investment funds managed by Pharmakon Advisors.
The US biotech – which has disclosed the name Cimerli for its biosimilar Lucentis candidate during the virtual 40th Annual J.P. Morgan Health Care Conference – has an FDA action date for its ophthalmology biosimilar candidate in August 2022